联成迅康

联成迅康 (Liancheng Xunkang), officially known as Sichuan Unireco Pharmaceutical, is a Chinese pharmaceutical company engaged in the research, development, production, and marketing of chemical drugs, traditional Chinese medicine (TCM) formulations, and TCM decoction pieces. Founded in 2007 and headquartered in Chengdu, Sichuan, the company operates a comprehensive business model spanning cultivation of authentic medicinal herbs, modern fermentation, and pharmaceutical manufacturing. Its subsidiary, Yaan Xunkang Pharmaceutical, serves as a key production base for specialized fermented TCM products. In April 2026, the company's innovative 1.1-class TCM drug, XKZ2305 Granules, received clinical trial approval from the NMPA for the treatment of pediatric asthma, marking a significant milestone in its R&D pipeline.